Goldkuhle Marius, Narayan Vikram M, Weigl Aaron, Dahm Philipp, Skoetz Nicole
Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Minneapolis Veterans Administration Health Care System and Department of Urology, University of Minnesota, Minneapolis, Minnesota, USA.
BMJ Open. 2018 Mar 25;8(3):e020869. doi: 10.1136/bmjopen-2017-020869.
To compare cancer-related systematic reviews (SRs) published in the Cochrane Database of SRs (CDSR) and high-impact journals, with respect to type, content, quality and citation rates.
Methodological SR with assessment and comparison of SRs and meta-analyses. Two authors independently assessed methodological quality using an Assessment of Multiple Systematic Reviews (AMSTAR)-based extraction form. Both authors independently screened search results, extracted content-relevant characteristics and retrieved citation numbers of the included reviews using the Clarivate Analytics Web of Science database.
Cancer-related SRs were retrieved from the CDSR, as well as from the 10 journals which publish oncological SRs and had the highest impact factors, using a comprehensive search in both the CDSR and MEDLINE.
We included all cancer-related SRs and meta-analyses published from January 2011 to May 2016. Methodological SRs were excluded.
We included 346 applicable Cochrane reviews and 215 SRs from high-impact journals. Cochrane reviews consistently met more individual AMSTAR criteria, notably with regard to an a priori design (risk ratio (RR) 3.89; 95% CI 3.10 to 4.88), inclusion of the grey literature and trial registries (RR 3.52; 95% CI 2.84 to 4.37) in their searches, and the reporting of excluded studies (RR 8.80; 95% CI 6.06 to 12.78). Cochrane reviews were less likely to address questions of prognosis (RR 0.04; 95% CI 0.02 to 0.09), use individual patient data (RR 0.03; 95% CI 0.01 to 0.09) or be based on non-randomised controlled trials (RR 0.04; 95% CI 0.02 to 0.09). Citation rates of Cochrane reviews were notably lower than those for high-impact journals (Cochrane reviews: mean number of citations 6.52 (range 0-143); high-impact journal SRs: 74.45 (0-652)).
When comparing cancer-related SRs published in the CDSR versus those published in high-impact medical journals, Cochrane reviews were consistently of higher methodological quality, but cited less frequently.
比较发表在Cochrane系统评价数据库(CDSR)和高影响力期刊上的癌症相关系统评价(SRs),涉及类型、内容、质量和引用率。
对SR和荟萃分析进行评估和比较的方法学SR。两位作者使用基于多系统评价评估(AMSTAR)的提取表独立评估方法学质量。两位作者独立筛选检索结果,提取与内容相关的特征,并使用科睿唯安的Web of Science数据库检索纳入评价的引用次数。
通过在CDSR和MEDLINE中进行全面检索,从CDSR以及10种发表肿瘤学SR且影响因子最高的期刊中检索癌症相关SR。
我们纳入了2011年1月至2016年5月发表的所有癌症相关SR和荟萃分析。排除方法学SR。
我们纳入了346篇适用的Cochrane评价和215篇来自高影响力期刊的SR。Cochrane评价始终满足更多的个体AMSTAR标准,特别是在事先设计方面(风险比(RR)3.89;95%可信区间3.10至4.88),在检索中纳入灰色文献和试验注册库(RR 3.52;95%可信区间2.84至4.37),以及报告排除的研究(RR 8.80;95%可信区间6.06至12.78)。Cochrane评价较少涉及预后问题(RR 0.04;95%可信区间0.02至0.09),较少使用个体患者数据(RR 0.03;95%可信区间0.01至0.09)或基于非随机对照试验(RR 0.04;95%可信区间0.02至0.09)。Cochrane评价的引用率明显低于高影响力期刊(Cochrane评价:平均引用次数6.52(范围0 - 143);高影响力期刊SR:74.45(0 - 652))。
在比较CDSR中发表的癌症相关SR与高影响力医学期刊中发表的SR时,Cochrane评价的方法学质量始终较高,但引用频率较低。